[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-369991-105":59,"doc-detail-369991-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","integration-of-whole-genome-sequencing-analysis-with-unique-patient-derived-models-reveals-clinically-relevant-drug-targets-in-tfcp2-fusion-defined-rhabdomyosarcoma","Integration of Whole-Genome Sequencing Analysis with Unique Patient-Derived Models Reveals Clinically Relevant Drug Targets in TFCP2 Fusion-Defined Rhabdomyosarcoma","","Precision medicine is positioned as a likely future approach, yet rare high-mortality, molecularly heterogeneous cancers lack effective therapies and relevant experimental models. The study focuses on TFCP2-rearranged rhabdomyosarcoma, establishing matched patient-derived xenograft and cell line models for intraosseous disease. Integrative multiomic and functional analyses identify alterations in oncogenic PI3K/AKT pathway networks. Dactolisib suppresses viability and tumor growth, and codeletion of nearby genes supports further testing of PRMT5 inhibition. Combined PRMT5 and PI3K/mTOR inhibition shows synergistic antitumor effects and improved in vivo survival.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/integration-of-whole-genome-sequencing-analysis-with-unique-patient-derived-models-reveals-clinically-relevant-drug-targets-in-tfcp2-fusion-defined-rhabdomyosarcoma/369991/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/integration-of-whole-genome-sequencing-analysis-with-unique-patient-derived-models-reveals-clinically-relevant-drug-targets-in-tfcp2-fusion-defined-rhabdomyosarcoma/369991.png","ImageObject",300,407,{"name":92,"@type":93},"kopisore","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-24","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":19},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What cancer subtype does the study investigate?","Question",{"text":112,"@type":113},"The study investigates TFCP2-rearranged rhabdomyosarcoma (RMS), specifically intraosseous disease models derived from patients.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What experimental models are developed for TFCP2-rearranged RMS?",{"text":117,"@type":113},"It establishes matched patient-derived xenograft and cell line models and combines them with comprehensive multiomic and functional analyses.",{"name":119,"@type":110,"acceptedAnswer":120},"Which therapeutic pathway and drugs show activity in preclinical testing?",{"text":121,"@type":113},"Alterations in gene networks tied to the oncogenic PI3K/AKT pathway are identified, and targeting this pathway with the PI3K/mTOR inhibitor dactolisib reduces viability in vitro and tumor growth in vivo.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},369991,1790922091,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":19,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":36,"preview_page_count":19,"preview_urls":145},962090880963,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Integration of Whole-Genome Sequencing Analysis with Unique Patient-Derived Models Reveals Clinically Relevant Drug Targets in TFCP2 Fusion–Defined Rhabdomyosarcoma  \nPatrick Bergsma1,2, Sean Porazinski1,3, Aji Istadi1, Diego Chacon-Fajardo1,3, Yasir Mahmood1, Silvia Lombardi1, Diana Schuhmacher1,3, Henry Barraclough-Franks1, Dario Strbenac4,  \nClaude V. Dennis5, Payam Faizi-Sobbi1, Emer Cahill1, Vivek A. Bhadri6,7, Jeneffer De Almeida Silva5, Trina Lum5, James Wykes7,8, Timothy Manzie7,8, Carsten E. Palme7,8, Jean Y. H. Yang4,  \nJonathan R. Clark7,8, Ruta Gupta5,8, and Marina Pajic1,3  \n|  |  | A |  | B | S |  | T | R |  | A |  | C | T |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n|  | Precision medicine is a likely future for all cancer treatment but may have its greatest impact on less common, high-mortality, and molecularly heterogeneous cancers. TFCP2-rearranged rhabdomyosarcoma (RMS) is a rare, aggressive cancer with poor survival due to the lack of effective therapies and relevant models to facilitate research. In this study, we establish the first matched patientderived xenograft and cell line model for TFCP2-rearranged intraosseous RMS, coupled with comprehensive multiomic and functional analyses, to discover and preclinically validate novel actionable molecular targets for this malignancy. Sequencing analyses of matched patient tumor and xenograft material revealed alterations in gene networks associated with the oncogenic, potentially targetable PI3K/AKT pathway. Preclinical assessments revealed that targeting the pathway with a small-molecule\u003Cbr>􀀶 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | PI3K/mTOR inhibitor dactolisib presents a promising treatment approach for this rare cancer, decreasing cancer cell viability in vitro and significantly reducing tumor growth in vivo. Parallel identification of the codeletion of adjacent genes cyclin-dependent kinase inhibitor 2A and methylthioadenosine phosphorylase in these tumors led us to further explore protein arginine methyltransferase 5 inhibition as a potential therapeutic approach. Strikingly, combined inhibition of protein arginine methyltransferase 5 and PI3K/mTOR signaling synergistically enhanced antitumor response and significantly improved survival in vivo. This study highlights the importance of new patient-derived models for the elucidation of the biology of rare cancers and identification of new therapeutic entry points, with clear implications for the future treatment of TFCP2-rearranged intraosseous RMS. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |\n\nIntroduction  \nMolecular-guided therapy is transforming the clinical management of a variety of solid cancers (1), including some of the hardestto-treat malignancies (2) . For many rare cancers, highlighting sarcoma as an example, new effective therapies are lacking and integrative computational analyses, robust preclinical models, and  \n1Translational Oncology Program, Garvan Institute of Medical Research, Syd","cbCain97EpOjP2Bp","https://ap.wps.com/l/cbCain97EpOjP2Bp","pdf",39265373,16,"English","# Introduction\n## Molecular-guided therapy and challenges in rare sarcomas\n## TFCP2-rearranged rhabdomyosarcoma background and rationale","[{\"question\":\"What cancer subtype does the study investigate?\",\"answer\":\"The study investigates TFCP2-rearranged rhabdomyosarcoma (RMS), specifically intraosseous disease models derived from patients.\"},{\"question\":\"What experimental models are developed for TFCP2-rearranged RMS?\",\"answer\":\"It establishes matched patient-derived xenograft and cell line models and combines them with comprehensive multiomic and functional analyses.\"},{\"question\":\"Which therapeutic pathway and drugs show activity in preclinical testing?\",\"answer\":\"Alterations in gene networks tied to the oncogenic PI3K/AKT pathway are identified, and targeting this pathway with the PI3K/mTOR inhibitor dactolisib reduces viability in vitro and tumor growth in vivo.\"}]","Integration of Whole-Genome Sequencing Analysis with Unique Patient-Derived Models Reveals Clinically Relevant Drug Targets in TFCP2 Fusion-Defined Rhabdomyosarcoma | PDF",1790186185,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cbaaae09f9f3a2d43924bda518913d1f.webp",983,1315,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bbb8372b2de38969b9be1caa6670822b.webp",982,1314,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5ccd2847c1dd27f4f650fe8c0efbec6a.webp",981,1312,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/95e4b06d85b56d26821f33acbbe01e0a.webp",980,1311]